https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659783/front-row-with-biocentury-cancer-s-next-wavehttps://www.biocentury.com/article/659783/front-row-with-biocentury-cancer-s-next-wave?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFRONT ROW WITH BIOCENTURY: CANCER’S NEXT WAVETranslational science driving clinical innovation in cancerThu, 18 Jun 2026 17:28:02 -0700https://www.biocentury.com/article/659823/kardigan-s-400m-ipo-is-latest-followed-by-aftermarket-gains-finance-reporthttps://www.biocentury.com/article/659823/kardigan-s-400m-ipo-is-latest-followed-by-aftermarket-gains-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKARDIGAN’S $400M IPO IS LATEST FOLLOWED BY AFTERMARKET GAINS: FINANCE REPORTPlus: series A rounds for MultiValent and Vedana, and moreThu, 18 Jun 2026 17:23:58 -0700https://www.biocentury.com/article/659836/continuing-signs-of-political-involvement-at-fdahttps://www.biocentury.com/article/659836/continuing-signs-of-political-involvement-at-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWCONTINUING SIGNS OF POLITICAL INVOLVEMENT AT FDAPost-Makary meetings with Replimune, Amgen and others raise questions about political access in regulatory disputesThu, 18 Jun 2026 16:59:54 -0700https://www.biocentury.com/article/659819/europe-s-narrow-path-between-the-u-s-and-china-in-biotechhttps://www.biocentury.com/article/659819/europe-s-narrow-path-between-the-u-s-and-china-in-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYEUROPE’S NARROW PATH BETWEEN THE U.S. AND CHINA IN BIOTECHEurope has an opening to become biotech’s third pole, but only if it engages China while anchoring IP, manufacturing, and development at homeThu, 18 Jun 2026 14:59:18 -0700https://www.biocentury.com/article/659785/vedana-taking-a-two-pathway-shot-at-migrainehttps://www.biocentury.com/article/659785/vedana-taking-a-two-pathway-shot-at-migraine?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEVEDANA: TAKING A TWO-PATHWAY SHOT AT MIGRAINESeattle-based biotech emerges with $46M series A to advance antibodies for migraineThu, 18 Jun 2026 13:25:58 -0700https://www.biocentury.com/article/659803/with-123m-to-invest-kos-aims-to-build-bridge-to-greek-biotech-ecosystemhttps://www.biocentury.com/article/659803/with-123m-to-invest-kos-aims-to-build-bridge-to-greek-biotech-ecosystem?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEWITH $123M TO INVEST, KOS AIMS TO BUILD BRIDGE TO GREEK BIOTECH ECOSYSTEMSimeonidis, Tzoukas aim to draw on ‘diaspora’ of talent to build connections to Southeastern European nationThu, 18 Jun 2026 13:23:55 -0700https://www.biocentury.com/article/659807/this-ai-moment-two-steps-forward-and-one-step-back-chris-arendthttps://www.biocentury.com/article/659807/this-ai-moment-two-steps-forward-and-one-step-back-chris-arendt?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONTHIS AI MOMENT: TWO STEPS FORWARD AND ONE STEP BACK – CHRIS ARENDTTakeda CSO in conversation at BioCentury Grand Rounds U.S. on successes and challenges of bringing AI into a 250-year-old pharma companyWed, 17 Jun 2026 18:10:02 -0700https://www.biocentury.com/article/659813/uniqure-reversal-puts-natural-history-controls-back-in-play-for-rare-neurohttps://www.biocentury.com/article/659813/uniqure-reversal-puts-natural-history-controls-back-in-play-for-rare-neuro?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTUNIQURE REVERSAL PUTS NATURAL-HISTORY CONTROLS BACK IN PLAY FOR RARE NEUROFDA’s U-turn on AMT-130 gives Huntington’s and other rare disease sponsors a counterweight to CBER’s earlier rejection of external-control dataWed, 17 Jun 2026 18:07:48 -0700https://www.biocentury.com/article/659808/senate-bill-seeks-to-enhance-dod-s-ability-to-sanction-chinese-companieshttps://www.biocentury.com/article/659808/senate-bill-seeks-to-enhance-dod-s-ability-to-sanction-chinese-companies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWSENATE BILL SEEKS TO ENHANCE DOD’S ABILITY TO SANCTION CHINESE COMPANIESSenate Armed Services Committee draft loosens criteria for 1260H designation, codifies and expands research security policiesWed, 17 Jun 2026 14:25:26 -0700https://www.biocentury.com/article/659804/memo-details-h-eg-s-role-in-blocking-tzield-approvalhttps://www.biocentury.com/article/659804/memo-details-h-eg-s-role-in-blocking-tzield-approval?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMEMO DETAILS HØEG’S ROLE IN BLOCKING TZIELD APPROVAL Former Acting CDER director overruled career scientists, failed to document evidence supporting her decisionsWed, 17 Jun 2026 13:45:39 -0700https://www.biocentury.com/article/659792/democrats-drug-pricing-policies-build-on-trump-s-foundationhttps://www.biocentury.com/article/659792/democrats-drug-pricing-policies-build-on-trump-s-foundation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWDEMOCRATS’ DRUG PRICING POLICIES BUILD ON TRUMP’S FOUNDATIONShort-term tactical concessions by pharmas have created a platform for proposals to sharply reduce industry revenuesTue, 16 Jun 2026 17:33:58 -0700https://www.biocentury.com/article/659723/nanophoria-delivering-inhalable-biologics-to-the-hearthttps://www.biocentury.com/article/659723/nanophoria-delivering-inhalable-biologics-to-the-heart?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILENANOPHORIA: DELIVERING INHALABLE BIOLOGICS TO THE HEARTNanotechnology company aims to route peptides and nucleic acids to cardiac tissue by way of the lung, backed by Italy’s largest biotech series ATue, 16 Jun 2026 16:52:02 -0700https://www.biocentury.com/article/659754/tuning-nanoparticles-to-each-tumor-barrierhttps://www.biocentury.com/article/659754/tuning-nanoparticles-to-each-tumor-barrier?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONTUNING NANOPARTICLES TO EACH TUMOR BARRIERFour nanoparticle platforms for solid tumors, three from China, each designed to clear a specific barrier — new in BioCentury's Innovation DistilleryTue, 16 Jun 2026 15:21:20 -0700https://www.biocentury.com/article/659772/novartis-taps-orionis-for-second-molecular-glue-tie-up-deals-reporthttps://www.biocentury.com/article/659772/novartis-taps-orionis-for-second-molecular-glue-tie-up-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSNOVARTIS TAPS ORIONIS FOR SECOND MOLECULAR GLUE TIE-UP: DEALS REPORTPlus: Lilly/AlzeCure, Verge/Tenacia, and moreMon, 15 Jun 2026 16:56:57 -0700https://www.biocentury.com/article/659773/biotech-ipos-biosecure-act-cachexia-pipeline-a-biocentury-podcasthttps://www.biocentury.com/article/659773/biotech-ipos-biosecure-act-cachexia-pipeline-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBIOTECH IPOS, BIOSECURE ACT, CACHEXIA PIPELINE — A BIOCENTURY PODCASTBiotech’s largest-ever IPO, leaders in the clinic for cachexia, and the latest from WashingtonMon, 15 Jun 2026 16:40:10 -0700https://www.biocentury.com/article/659777/tzield-approval-another-sign-makary-era-overhttps://www.biocentury.com/article/659777/tzield-approval-another-sign-makary-era-over?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTZIELD APPROVAL ANOTHER SIGN MAKARY ERA OVERFDA’s approval of an sBLA for Tzield comes after a chaotic ride through Makary’s FDAMon, 15 Jun 2026 16:38:09 -0700https://www.biocentury.com/article/659776/rhythm-builds-case-for-phase-iii-in-prader-willihttps://www.biocentury.com/article/659776/rhythm-builds-case-for-phase-iii-in-prader-willi?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTRHYTHM BUILDS CASE FOR PHASE III IN PRADER-WILLI Six-month setmelanotide data show improvements across weight, hyperphagia and behavior, while Elicio and Neumora suffer clinical setbacksMon, 15 Jun 2026 16:30:28 -0700https://www.biocentury.com/article/659762/new-ceos-at-dualitas-apnimed-vergent-and-oriva-management-trackshttps://www.biocentury.com/article/659762/new-ceos-at-dualitas-apnimed-vergent-and-oriva-management-tracks?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNEW CEOS AT DUALITAS, APNIMED, VERGENT AND ORIVA: MANAGEMENT TRACKSPlus: Ambros taps pair of Regulus vets; the U.K.’s BIA gets a new CEO; and moreFri, 12 Jun 2026 16:04:33 -0700https://www.biocentury.com/article/659763/wuxi-apptec-contests-military-designationhttps://www.biocentury.com/article/659763/wuxi-apptec-contests-military-designation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWUXI APPTEC CONTESTS MILITARY DESIGNATIONLawsuit refutes government assertions, lists harms beyond BiosecureFri, 12 Jun 2026 15:58:48 -0700https://www.biocentury.com/article/659739/houston-s-translational-moment-looks-beyond-its-clinical-prowesshttps://www.biocentury.com/article/659739/houston-s-translational-moment-looks-beyond-its-clinical-prowess?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONHOUSTON’S TRANSLATIONAL MOMENT LOOKS BEYOND ITS CLINICAL PROWESSThe city has a dedicated effort to turn its clinical depth, manufacturing and capital into a repeatable path from discovery to medicinesFri, 12 Jun 2026 15:48:11 -0700https://www.biocentury.com/article/659756/the-horizon-just-got-closer-letter-from-the-editorhttps://www.biocentury.com/article/659756/the-horizon-just-got-closer-letter-from-the-editor?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYTHE HORIZON JUST GOT CLOSER: LETTER FROM THE EDITORBioCentury is expanding its horizon-scanning tools, data, and analysis to help drug hunters track where translational science is heading nextFri, 12 Jun 2026 15:46:04 -0700https://www.biocentury.com/article/659752/parabilis-completes-770m-ipo-as-kardigan-lines-up-in-queue-public-equity-reporthttps://www.biocentury.com/article/659752/parabilis-completes-770m-ipo-as-kardigan-lines-up-in-queue-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEPARABILIS COMPLETES $770M IPO AS KARDIGAN LINES UP IN QUEUE: PUBLIC EQUITY REPORTPlus: Follow-ons for Tango and Enliven, and moreFri, 12 Jun 2026 13:58:56 -0700https://www.biocentury.com/article/659713/making-als-heterogeneity-tractable-mcgill-s-angela-gengehttps://www.biocentury.com/article/659713/making-als-heterogeneity-tractable-mcgill-s-angela-genge?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMAKING ALS HETEROGENEITY TRACTABLE — MCGILL’S ANGELA GENGEALS clinical trials veteran Genge sees progress in pathway prioritization, progression modeling, endpoint execution and biomarker developmentFri, 12 Jun 2026 13:45:17 -0700https://www.biocentury.com/article/659459/gdf15-emerges-as-cachexia-s-lead-target-with-pfizer-and-catalym-in-phase-ii-iiihttps://www.biocentury.com/article/659459/gdf15-emerges-as-cachexia-s-lead-target-with-pfizer-and-catalym-in-phase-ii-iii?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTGDF15 EMERGES AS CACHEXIA’S LEAD TARGET, WITH PFIZER AND CATALYM IN PHASE II/IIIThe cytokine sits at the intersection of tumor immune evasion and muscle wasting, offering drug developers a rare chance to address both at onceFri, 12 Jun 2026 09:38:17 -0700https://www.biocentury.com/article/659743/it-s-about-time-how-the-political-calendar-will-shape-biopharma-s-futurehttps://www.biocentury.com/article/659743/it-s-about-time-how-the-political-calendar-will-shape-biopharma-s-future?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWIT’S ABOUT TIME: HOW THE POLITICAL CALENDAR WILL SHAPE BIOPHARMA’S FUTUREElections and legislative deadlines will likely keep Kennedy in place through November, slow FDA leadership changes, and set the pace for FDA reformThu, 11 Jun 2026 16:37:24 -0700https://www.biocentury.com/article/659742/ethyreal-launches-with-101m-aiming-to-compete-in-tepezza-s-arena-venture-reporthttps://www.biocentury.com/article/659742/ethyreal-launches-with-101m-aiming-to-compete-in-tepezza-s-arena-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEETHYREAL LAUNCHES WITH $101M, AIMING TO COMPETE IN TEPEZZA’S ARENA: VENTURE REPORTPlus: Fundings for Beren, City, and moreThu, 11 Jun 2026 14:17:35 -0700https://www.biocentury.com/article/659705/two-healthcare-investors-go-global-togetherhttps://www.biocentury.com/article/659705/two-healthcare-investors-go-global-together?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCETWO HEALTHCARE INVESTORS GO GLOBAL TOGETHERMerger of GHO Capital and CBC Group combine complementary investment strategies, geographiesThu, 11 Jun 2026 09:06:55 -0700https://www.biocentury.com/article/659695/building-a-biomarker-stack-to-stratify-alzheimer-s-trialshttps://www.biocentury.com/article/659695/building-a-biomarker-stack-to-stratify-alzheimer-s-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONBUILDING A BIOMARKER STACK TO STRATIFY ALZHEIMER’S TRIALSBioCentury’s revamped Innovation Distillery highlights Alzheimer’s biomarkers that could enrich trials, stage disease and link biology to functionThu, 11 Jun 2026 08:03:56 -0700https://www.biocentury.com/article/659475/pinnacle-designing-oral-peptides-to-close-the-gap-with-injectable-biologicshttps://www.biocentury.com/article/659475/pinnacle-designing-oral-peptides-to-close-the-gap-with-injectable-biologics?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEPINNACLE: DESIGNING ORAL PEPTIDES TO CLOSE THE GAP WITH INJECTABLE BIOLOGICSBiotech will take an oral peptide for COPD into the clinic by year-end, backed by an $89M series B announced in MarchWed, 10 Jun 2026 16:27:24 -0700https://www.biocentury.com/article/659729/moving-faster-at-the-academia-industry-interface-a-biocentury-podcasthttps://www.biocentury.com/article/659729/moving-faster-at-the-academia-industry-interface-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONMOVING FASTER AT THE ACADEMIA-INDUSTRY INTERFACE — A BIOCENTURY PODCASTTakeaways from BioCentury’s 3rd Grand Rounds U.S. - SeattleWed, 10 Jun 2026 16:02:36 -0700https://www.biocentury.com/article/659607/lrrk2-inhibitor-failure-pushes-parkinson-s-field-toward-genetic-enrichmenthttps://www.biocentury.com/article/659607/lrrk2-inhibitor-failure-pushes-parkinson-s-field-toward-genetic-enrichment?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTLRRK2 INHIBITOR FAILURE PUSHES PARKINSON’S FIELD TOWARD GENETIC ENRICHMENTWith Biogen and Denali’s BIIB122 missing in Parkinson's all-comers, the question may no longer be whether to enrich trial populations, but howWed, 10 Jun 2026 15:36:30 -0700https://www.biocentury.com/article/659719/where-parabilis-massive-ipo-ranks-among-biotech-debuts-on-nasdaqhttps://www.biocentury.com/article/659719/where-parabilis-massive-ipo-ranks-among-biotech-debuts-on-nasdaq?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEWHERE PARABILIS’ MASSIVE IPO RANKS AMONG BIOTECH DEBUTS ON NASDAQOffering’s total size still depends on underwriters’ optionWed, 10 Jun 2026 14:46:50 -0700https://www.biocentury.com/article/659612/the-race-for-a-vaccine-against-rare-ebola-virushttps://www.biocentury.com/article/659612/the-race-for-a-vaccine-against-rare-ebola-virus?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE RACE FOR A VACCINE AGAINST RARE EBOLA VIRUSCEPI’s $60M-plus commitment aims to push Bundibugyo virus candidates toward the clinic as outbreak risk growsTue, 09 Jun 2026 17:48:51 -0700https://www.biocentury.com/article/659554/mhra-proposes-pairing-trial-authorization-with-market-access-for-very-rare-diseaseshttps://www.biocentury.com/article/659554/mhra-proposes-pairing-trial-authorization-with-market-access-for-very-rare-diseases?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMHRA PROPOSES PAIRING TRIAL AUTHORIZATION WITH MARKET ACCESS FOR VERY RARE DISEASESU.K. regulator unveils a flexible new approval pathway to drive rare disease drug development — but reimbursement remains unresolvedTue, 09 Jun 2026 17:39:07 -0700https://www.biocentury.com/article/659707/in-third-deal-under-miels-gsk-adds-targeted-cancer-therapies-via-10-6b-nuvalent-buyhttps://www.biocentury.com/article/659707/in-third-deal-under-miels-gsk-adds-targeted-cancer-therapies-via-10-6b-nuvalent-buy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSIN THIRD DEAL UNDER MIELS, GSK ADDS TARGETED CANCER THERAPIES VIA $10.6B NUVALENT BUYPharma set to add ROS1, ALK programs that could win approval this year; deal is exit for longtime investor DeerfieldTue, 09 Jun 2026 17:16:12 -0700https://www.biocentury.com/article/659709/impact-of-biosecure-starting-to-come-into-focushttps://www.biocentury.com/article/659709/impact-of-biosecure-starting-to-come-into-focus?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWIMPACT OF BIOSECURE STARTING TO COME INTO FOCUSWuXi AppTech to contest its designation as a Chinese military companyTue, 09 Jun 2026 16:02:24 -0700https://www.biocentury.com/article/659699/calmer-waters-for-fda-servier-lilly-deals-a-biocentury-podcasthttps://www.biocentury.com/article/659699/calmer-waters-for-fda-servier-lilly-deals-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONCALMER WATERS FOR FDA; SERVIER, LILLY DEALS — A BIOCENTURY PODCASTNew leaders set tone at FDA; billion-dollar deals pace biopharma BDMon, 08 Jun 2026 18:03:01 -0700https://www.biocentury.com/article/659674/sizing-up-lilly-s-dealmaking-spreehttps://www.biocentury.com/article/659674/sizing-up-lilly-s-dealmaking-spree?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTESIZING UP LILLY’S DEALMAKING SPREEMegacap commits over $45B towards M&A and partnerships so far in 2026Mon, 08 Jun 2026 17:57:56 -0700https://www.biocentury.com/article/659684/tango-s-prmt5-inhibitor-adds-to-daraxonrasib-activity-in-pancreatic-cancerhttps://www.biocentury.com/article/659684/tango-s-prmt5-inhibitor-adds-to-daraxonrasib-activity-in-pancreatic-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTANGO’S PRMT5 INHIBITOR ADDS TO DARAXONRASIB ACTIVITY IN PANCREATIC CANCERVopimetostat becomes the first to show potential additive efficacy with the pan-RAS inhibitor in PDACMon, 08 Jun 2026 15:29:25 -0700https://www.biocentury.com/article/659688/j-j-firefly-roche-nurix-each-strike-degrader-deals-deals-reporthttps://www.biocentury.com/article/659688/j-j-firefly-roche-nurix-each-strike-degrader-deals-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSJ&J/FIREFLY, ROCHE/NURIX EACH STRIKE DEGRADER DEALS: DEALS REPORTPlus: Incyte/Vega; GSK/Engitix; Lilly/Ascidian; and moreMon, 08 Jun 2026 15:11:42 -0700https://www.biocentury.com/article/659686/in-its-largest-m-a-deal-incyte-adds-late-stage-bleeding-candidate-via-vega-buyhttps://www.biocentury.com/article/659686/in-its-largest-m-a-deal-incyte-adds-late-stage-bleeding-candidate-via-vega-buy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSIN ITS LARGEST M&A DEAL, INCYTE ADDS LATE-STAGE BLEEDING CANDIDATE VIA VEGA BUYStructure of $1.25B deal funnels returns to shareholders through holding company Star; milestones could bring total value to $2BMon, 08 Jun 2026 14:10:31 -0700https://www.biocentury.com/article/659644/may-s-approvals-bring-fda-to-20-nmes-on-the-yearhttps://www.biocentury.com/article/659644/may-s-approvals-bring-fda-to-20-nmes-on-the-year?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMAY’S APPROVALS BRING FDA TO 20 NMES ON THE YEARA look at last month’s approvals in the U.S.Fri, 05 Jun 2026 18:10:40 -0700https://www.biocentury.com/article/659660/ona-s-86-6m-venture-round-among-spain-s-biggest-for-a-biotech-finance-reporthttps://www.biocentury.com/article/659660/ona-s-86-6m-venture-round-among-spain-s-biggest-for-a-biotech-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEONA’S $86.6M VENTURE ROUND AMONG SPAIN’S BIGGEST FOR A BIOTECH: FINANCE REPORTPlus: Massive round for NewLimit; follow-ons for Jade and Mineralys; LongBio’s Hong Kong listing; and moreFri, 05 Jun 2026 17:53:34 -0700https://www.biocentury.com/article/659671/adcs-headline-first-in-human-development-at-ascohttps://www.biocentury.com/article/659671/adcs-headline-first-in-human-development-at-asco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTADCS HEADLINE FIRST-IN-HUMAN DEVELOPMENT AT ASCO BioCentury’s analysis of 137 FIH studies highlighted at this year’s conferenceFri, 05 Jun 2026 17:48:56 -0700https://www.biocentury.com/article/659676/forbion-welcomes-mcdonald-from-novo-promotes-two-partnershttps://www.biocentury.com/article/659676/forbion-welcomes-mcdonald-from-novo-promotes-two-partners?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSFORBION WELCOMES MCDONALD FROM NOVO, PROMOTES TWO PARTNERSPlus: Management changes at Airna, Myriad Genetics and OncolyticsFri, 05 Jun 2026 17:29:32 -0700https://www.biocentury.com/article/659662/fred-hutch-s-sylvain-simon-named-rising-star-at-grand-rounds-u-s-in-seattlehttps://www.biocentury.com/article/659662/fred-hutch-s-sylvain-simon-named-rising-star-at-grand-rounds-u-s-in-seattle?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONFRED HUTCH’S SYLVAIN SIMON NAMED ‘RISING STAR’ AT GRAND ROUNDS U.S. IN SEATTLEChimeric T cell receptor platform could help prevent cancer relapse seen with CAR T cell therapiesThu, 04 Jun 2026 16:51:32 -0700https://www.biocentury.com/article/659669/meeting-sign-of-acting-fda-leadership-trying-to-right-the-shiphttps://www.biocentury.com/article/659669/meeting-sign-of-acting-fda-leadership-trying-to-right-the-ship?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMEETING SIGN OF ACTING FDA LEADERSHIP TRYING TO RIGHT THE SHIPIn gathering with rare disease advocates, agency leadership stresses return to normal operations, respect for career staff, transparencyThu, 04 Jun 2026 16:32:22 -0700https://www.biocentury.com/article/659657/congressional-concern-growing-over-integration-of-chinese-u-s-biopharmahttps://www.biocentury.com/article/659657/congressional-concern-growing-over-integration-of-chinese-u-s-biopharma?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWCONGRESSIONAL CONCERN GROWING OVER INTEGRATION OF CHINESE, U.S. BIOPHARMA Legislation to limit in-licensing, add biotech to outbound investment controls pressures Trump administration to curtail biopharma engagement with ChinaThu, 04 Jun 2026 16:16:35 -0700https://www.biocentury.com/article/659622/servier-continues-m-a-buildout-acquires-edgewise-s-neuro-programshttps://www.biocentury.com/article/659622/servier-continues-m-a-buildout-acquires-edgewise-s-neuro-programs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSSERVIER CONTINUES M&A BUILDOUT, ACQUIRES EDGEWISE’S NEURO PROGRAMS$1.6B buyout for sevasemten marks first big neuro move for ServierThu, 04 Jun 2026 13:19:46 -0700https://www.biocentury.com/article/659653/legend-s-ex-vivo-design-expertise-underpins-in-vivo-car-t-efficacyhttps://www.biocentury.com/article/659653/legend-s-ex-vivo-design-expertise-underpins-in-vivo-car-t-efficacy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTLEGEND’S EX VIVO DESIGN EXPERTISE UNDERPINS IN VIVO CAR T EFFICACYLegend CEO Ying Huang discusses first-in-human in vivo CAR T results with BioCenturyWed, 03 Jun 2026 17:52:06 -0700